ASCRS Live: Aurion BioTech shares 12-month data from their recent Escalón trial

Ophthalmology Times© spoke with Greg Kunst about Aurion BioTech's 12-month data from their recent Escalón trial 2023 at the ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Greg Kunst:

Hi, I'm Greg Kunst, CEO of Aurion Biotech. We're here at the ASCRS this week talking about the release of our 12-month data from our recent Escalón trial. Our Escalón trial is our Phase 1 trial...where we're able to demonstrate in 12 months significant that percentage of patients should have three lines of improvement in vision of over 90%...central corneal thickness back to healthy levels. Once again another trials demonstrating that our cell therapy is highly effective and very safe. We're now moving towards clinical trials in the United States. Additionally, we recently got approval in Japan as well for our drug and so we're excited about it. We started our commercial prospects in Japan, our first major market in the world where we're cell therapy approved.

Lastly, we recently received the Prix Galien Award, which is perceived to be one of the highest awards in biotech. That award was really a testament to the work that we're doing, the degree of unmet need that we're trying to address around the world to really put an end to corneal blindness in many parts of the world. We know that 77 million people in the world are corneal blind and they lack access to corneal tissue. I think it really that's the promise of what we're trying to accomplish with cell therapy. Thank you very much.